C-Further has unveiled its first early-stage therapeutic programmes dedicated to paediatric oncology indications. 

The international consortium is set to advance CF-012 for the treatment of Ewing sarcoma, in collaboration with investigators at UVA Comprehensive Cancer Center, Dana-Farber Cancer Institute and Mass General Brigham, and has also partnered with MiNK Therapeutics to advance CF-033 for the treatment of children’s cancers. 

CF-012 targets ETV6, a newly identified and critical transcriptional dependency that is essential for tumour growth and metastasis. C-Further aims to develop a potential first-in-class inhibitor with a precise mechanism to disrupt tumour growth and metastasis in young patients. 

Meanwhile, CF-033 is a potential first-in-class allogeneic iNKT cell therapy engineered with a specific T-cell receptor targeting PRAME. The therapy bridges innate and adaptive immunity and is designed to enable both direct tumour cell killing and broader immune activation within the tumour microenvironment.  

As an allogeneic, off-the-shelf approach without the need for toxic lymphodepletion, CF-033 could support more timely treatment delivery and improved tolerability, which are important considerations in paediatric oncology, where new therapeutic approaches are urgently needed. 

“By combining the pioneering approaches of our scientific collaborators with industry-standard drug discovery capabilities, expertise of our core partners and reach into critical paediatric-focused networks, C-Further is advancing a pipeline of potential first-in-class therapies for childhood cancers,” said Lone Friis, C-Further Programme Co-Lead.  

“Guided by an indication-agnostic but child-first approach, we believe the initial CF-012 and CF-033 programmes have the potential to address a profound unmet need across multiple children’s cancers.” 

Additional C-Further programmes are set to be announced later in 2026.